In the fall of 2005, GlaxoSmithKline called attention to recentlycollected safety data indicating an increased risk of majorcongenital malformations among infants exposed during organogenesisto GlaxoSmithKline's selective serotonin reuptake inhibitor(SSRI), paroxetine. Among 527 fetuses exposed to paroxetinein the first trimester, 23 were born with major congenital malformations.Most of the malformations were cardiovascular, and the majorityof those were ventricular septal defects. As compared with infantsborn to women taking any other antidepressant agent during thefirst trimester, the adjusted odds ratio for any malformationwas 2.2 (95% confidence interval [CI], 1.3 to 3.6). Previouslypublished . . . [Full Text of this Article]
Source Information
From the Division of MaternalFetal Medicine, Massachusetts General Hospital, Boston.
This article has been cited by other articles:
Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., Jovanovic, L. B., Kjos, S. I., Knopp, R. H., Montoro, M. N., Ogata, E. S., Paramsothy, P., Reader, D. M., Rosenn, B. M., Thomas, A. M., Kirkman, M. S.
(2008). Managing Preexisting Diabetes for Pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care
31: 1060-1079
[Full Text]
Yonkers, K. A.
(2007). The Treatment of Women Suffering From Depression Who Are Either Pregnant or Breastfeeding. Am. J. Psychiatry
164: 1457-1459
[Full Text]
(2007). SSRIs in First-Trimester Pregnancy: Small Risks to the Fetus. JWatch Psychiatry
2007: 1-1
[Full Text]
(2007). SSRIs and Birth Defects -- How Concerned Should Our Patients Be?. JWatch Women's Health
2007: 1-1
[Full Text]
(2007). Do SSRIs Cause Birth Defects?. JWatch General
2007: 1-1
[Full Text]